IgA transcytosis: A new weapon in the immune response to cancer?

Tumor-infiltrating B cells and plasma cells have emerged as critical players in anti-tumor immunity. A recent report in Nature shows that IgA antibodies produced by these cells can enter tumor cells by transcytosis, impede oncogenic signals, and facilitate T cell-mediated cytotoxicity. These findings reveal a promising new mechanism to exploit for immunotherapy.

Automated summary

The research demonstrates that IgA antibodies produced by tumor-infiltrating B cells and plasma cells can enter tumor cells via transcytosis, inhibiting oncogenic signals and enhancing T cell-mediated cytotoxicity. These findings unveil a promising new avenue for immunotherapy.